Tegsedi Akcea Therapeutics Ireland Limited · Authorised · authorised 6 Jul 2018 · ATC N07
Therapeutic indication (EMA)
Treatment of stage 1 or Stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR).
Active substance
Inotersen
- US FDA 1
- EMA 1
- Safety 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| TEGSEDI | EQ 284MG BASE/1.5ML (EQ 189.3MG BASE/ML) | solution · subcutaneous | AKCEA THERAPS | Discontinued | 5 Oct 2018 |
EMA European Union — centrally authorised medicines
Safety signals and safety-related labeling changes
- US FDA 12 Jan 2024 TEGSEDI — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.